EXEL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EXEL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Exelixis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0 Mil. Exelixis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $201 Mil. Exelixis's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $2,128 Mil. Exelixis's debt to equity for the quarter that ended in Mar. 2024 was 0.09.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Exelixis's Debt-to-Equity or its related term are showing as below:
During the past 13 years, the highest Debt-to-Equity Ratio of Exelixis was 107.61. The lowest was -6.07. And the median was 0.03.
The historical data trend for Exelixis's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exelixis Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-Equity | Get a 7-Day Free Trial | 0.03 | 0.03 | 0.02 | 0.08 | 0.08 |
Exelixis Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Debt-to-Equity | Get a 7-Day Free Trial | 0.07 | 0.08 | 0.08 | 0.08 | 0.10 |
For the Biotechnology subindustry, Exelixis's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Exelixis's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Exelixis's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Exelixis's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0 | + | 189.944) | / | 2263.912 | |
= | 0.08 |
Exelixis's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0 | + | 201.466) | / | 2128.008 | |
= | 0.09 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exelixis (NAS:EXEL) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Exelixis's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Patrick J. Haley | officer: Sr. Vice President, Commercial | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Jeffrey Hessekiel | officer: EVP and General Counsel | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
David Edward Johnson | director | 590 MADISON AVENUE, NEW YORK NY 10022 |
Dana Aftab | officer: CSO/EVP Disc & Trans Research | EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502 |
Amy C. Peterson | officer: EVP Prod Dev & Med Aff & CMO | C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108 |
Christopher J. Senner | officer: EVP and CFO | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Tomas J. Heyman | director | C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Bob Oliver | director | C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Caligan Partners Lp | director, other: See Remarks | 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022 |
Jack L Wyszomierski | director | SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000 |
Alan M Garber | director | 3355 MILTON COURT, MOUNTAIN VIEW CA 94040 |
Carl B Feldbaum | director | C/O EXELIXIS INC, 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRISCISCO CA 94083-0511 |
Peter Lamb | officer: EVP, Discovery Research & CSO | PO BOX 511, 170 HARBOR WAY, SOUTH SAN FRANCISCO CA 94083-0511 |
George Poste | director | 515 GALVESTON DR, REDWOOD CITY CA 94063 |
Lance Willsey | director | C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083 |
From GuruFocus
By Business Wire Business Wire • 05-07-2023
By Business Wire Business Wire • 05-30-2023
By Business Wire • 08-21-2023
By Business Wire Business Wire • 03-02-2023
By Business Wire Business Wire • 05-03-2023
By Business Wire • 08-23-2023
By Business Wire • 12-07-2023
By Business Wire Business Wire • 05-01-2023
By Business Wire • 11-21-2023
By Business Wire Business Wire • 05-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.